The clinical trial to examine the efficacy of the intravitreal injection of anti-VEGF antibody Bevacizumab(Avastin) for severe retinopathy of prematurity.
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Bevacizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- 28 Jun 2017 New trial record